Cidara Therapeutics Inc.
Merck to Acquire Cidara Therapeutics for $9.2 Billion
Summary
Cidara Therapeutics, Inc. has entered into a definitive merger agreement with Merck Sharp & Dohme LLC, a subsidiary of Merck, for an acquisition price of $221.50 per share in cash, totaling approximately $9.2 billion. The transaction, which has been approved by both companies' Boards of Directors, is expected to close in the first quarter of 2026 and will be accounted for as an asset acquisition. The merger will see Cidara become a wholly-owned subsidiary of Merck, bolstering Merck's pipeline with Cidara's lead candidate, CD388, an investigational long-acting antiviral agent designed to prevent influenza. The deal includes a tender offer for Cidara's shares and is subject to customary closing conditions, including regulatory approvals and the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement